VISFATIN MAY SERVE AS AN EFFECTIVE EARLY INDICATOR FOR DETECTION OF GESTATIONAL DIABETES MELLITUS

Main Article Content

Syed Bakht Ruidar
Wang Ning
Syed Ali Raza

Keywords

Visfatin, Gestational Diabetes, Pregnant Females, Oral glucose tolerance test, GDM Detection

Abstract

Objective: The current study aims to determine whether an increase in visfatin level resulted in Gestational Diabetes Mellitus (GDM) in pregnant females.


Study Design: Retrospective Study


Place and Duration: Department of Medicine, Dr. Ziauddin Hospital, North Nazimabad, Karachi, From December 2021 to May 2022.


Methods: In this study, 83 pregnant females aged 18-40 years were inducated. After obtaining informed written consent, detailed demographic data were recorded. Gestational age and gravidity among all females were recorded. Previous history and frequency of GDM were assessed. Blood samples were taken to determine the concentration of visfatin and glucose levels. SPSS 24.0 was used to analyze all data.


Results: In this study, the mean age was 25.11±8.42 years, and the mean BMI was 28.2±3.32 kg/m2. The mean gestational age was 25.11±2.33 weeks. Most of the cases were from rural areas and had poor socio-economic status. We found that 44 (53.01%) subjects had gestational diabetes mellitus while 39 (46.9%) had no diabetes. The visfatin level in patients with gestational diabetes was higher, 4.2±7.124, compared to non-diabetes cases, 1.4±1.432, with a p-value<0.003.


Conclusion: Ultimately, we determined that visfatin levels were considerably elevated in gestational diabetes mellitus beginning in the first trimester of pregnancy. An innovative biomarker for GDM detection is increased visfatin levels during pregnancy.

Abstract 52 | pdf Downloads 37

References

1. Filippatos TD, Derdemezis CS, Gazi IF, Lagos K, Kiortsis DN, Tselepis AD, et al. Increased plasma visfatin levels in subject with metabolic syndrome. Eur J Clin Invest 2008;38:71–2.
2. Xu J, Zhao YH, Chen YP, Yuan XL, Wang J, Zhu H, Lu CM. Maternal circulating concentrations of tumor necrosis factoralpha, leptin, and
3. Pedersen J. Diabetes and pregnancy; blood sugar of new born infants during fasting and glucose administration. Ugeskr Laeger.1952;114(21):68.4
4. Seshiah V, Cynthia A, Balaji V, Balaji M S, Arthi T. Detection and care of women with gestational diabetes mellitus from early weeks of pregnancy results in birth weight of new born babies appropriate for gestational age. Diabetes research and clinical practice, 2008, vol. 80, 2, pp. 199-202
5. Clausen T D, Mathiesen E R, Hansen T et al. High Prevalence of Type 2 Diabetes and Pre-Diabetes in Adult Offspring of Women with Gestational Diabetes Mellitus or Type 1 Diabetes – The Role of Intrauterine Hyperglycemia. Diabetes Care 2008 31 340-346
6. Clausen T D, Mathiesen E R, Hansen T et al. High Prevalence of Type 2 Diabetes and Pre-Diabetes in Adult Offspring of Women with Gestational Diabetes Mellitus or Type 1 Diabetes – The Role of Intrauterine Hyperglycemia. Diabetes Care 2008 31 340-346
7. Köninger A, Mathan A, Mach P, Frank M, Schmidt B, Schleussner E, et al. Is afamin a novel biomarker for gestational diabetes mellitus? A pilot study. Reprod Biol Endocrinol. 2018;16:30
8. Li YY, Xiao R, Li CP, Huangfu J, Mao JF. Increased plasma levels of FABP4 and PTEN is associated with more severe insulin resistance in women with gestational diabetes mellitus. Med Sci Monit. 2015;8(21):426-431
9. Kaygusuz I, Gumus II, Yılmaz S, Simavlı S, Uysal S, Derbent AU, et al. Serum levels of visfatin and possible interaction with iron parameters in gestational diabetes mellitus. Gynecol Obstet Inves 2013;75(3):203–9
10. Ma Y, Cheng Y, Wang J, Cheng H, Zhou S, Li X. The changes of visfatin in serum and its expression in fat and placental tissue in pregnant women with gestational diabetes. Diabetes Res Clin Pract 2010;90(1):60–5s
11. Görkem Ü, Küçükler FK, Toğrul C, Güngör T. Are adipokines associated with gestational diabetes mellitus? J Turk Ger Gynecol Assoc 2016;17(4):186–90. .
12. Jieyu H, Chao T, Mengjun L, Shalong W, Xiaomei G, Jianfeng L, et al. NAMPT/visfsatin/PBEF: a functional multi-faceted protein with a pivotal role in malignant tumors. Curr Pharm Des 2012;18(37):6123– 32
13. Asare-Anane H, Bawah AT, Osa-Andrews B, Adanu R, Ofori E, Bani S, et al. Lipid Profile in Ghanaian Women with Gestational Diabetes Mellitus. Int J Sci Technol Res 2013;2(4):168–75.
14. Kaygusuz I, Gumus II, Yılmaz S, Simavlı S, Uysal S, Derbent AU, et al. Serum levels of visfatin and possible interaction with iron parameters in gestational diabetes mellitus. Gynecol Obstet Inves 2013;75(3):203–9.
15. Park HS, Park JY, Yu R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-α and IL-6. Diabetes Res Clin Pract. 2005;69:29–35.
16. Lekva T, Norwitz ER, Aukrust P, Ueland T. Impact of Systemic Inflammation on the Progression of Gestational Diabetes Mellitus. Curr Diab Rep. 2016;16:26. 10.1007/s11892-016-0715-9
17. Huhn EA, Rossi SW, Hoesli I, Gobl CS. Controversies in screening and diagnostic criteria for GDM in early and late pregnancy. Front Endocrinol (Lausanne). 2018;9:696.
18. Gorkem U, Togrul C, Arslan E. Relationship between elevated serum level of placental growth factor and status of gestational diabetes mellitus. J Matern Fetal Neonatal Med. 2020;33:4159–63.
19. Nuzzo AM, Giuffrida D, Moretti L, Re P, Grassi G, Menato G, et al. Placental and maternal sFlt1/PIGF expression in gestational diabetes mellitus. Sci Rep. 2021;11:2312.
20. Bawah, AT Seini MM, Abaka-Yawason A, Alidu H, Nanga S. Leptin, resistin and visfatin as useful predictors of gestational diabetes mellitus. Lipids Health Dis 2019;18(1):221.
21. Omazić J, Viljetić B, Ivić V, Kadivnik M, Zibar L, Müller A, Wagner J. Early markers of gestational diabetes mellitus: what we know and which way forward? Biochem Med (Zagreb). 2021 Oct 15;31(3):030502.

Most read articles by the same author(s)